MELISSA INCREASES SALES AND SUPPORT FOR CHINA BUSINESS

Growing Asia Pacific focus reflects foundational nature of address management in global business operations and customer communications

RANCHO SANTA MARGARITA, Calif., Sept 28 (Bernama-GLOBE NEWSWIRE) -- Melissa, a leading provider of global data quality and address management solutions, today announced its increased sales and support for China business, extending the company’s reach and reflecting the importance of rapidly expanding Asia Pacific markets seeking data quality tools and services.

Melissa recognizes that smart address management is foundational to smooth business operations. The company’s tools are global in nature and optimized to drive improved business communications, more profitable customer relationships, and competitive advantage. Services are broadly applicable to any firm with a diverse customer base, and largely deployed in financial services, healthcare, and ecommerce.

“Excellence in customer data is grounded in the basics of correct, complete addresses – providing a strong foundation for critical activities that ideally occur in real-time, such as Know Your Customer initiatives, identity verification and anti-fraud measures, and seamless customer onboarding,” said, Edmund Ng, Regional Sales Director, Asia Pacific, Melissa. “With our current global footprint, we are a proven data resource for businesses based in Japan, Hong Kong, and Singapore. We value a high level of local support and technical expertise, and now can add even greater value to Asia Pacific markets.”

Melissa’s global offices offer convenient, in-country access to Melissa services and personnel. The company’s worldwide footprint also includes offices in North America, Germany, the United Kingdom, India, Australia, and Singapore. Call +65-8-2997442 or email info.cn@melissa.com to connect directly with staff supporting Melissa’s Asia Pacific business. To connect with other members of Melissa’s global intelligence team, visit https://www.melissa.com/ or call 1-800-MELISSA.

About Melissa

Since 1985, Melissa has specialized in global intelligence solutions to help organizations unlock accurate data for a more compelling customer view. More than 10,000 clients worldwide in arenas such as retail, education, healthcare, insurance, finance, and government, rely on Melissa for full spectrum data quality and ID verification software, including data matching, validation, and enhancement services to gain critical insight and drive meaningful customer relationships. For more information or free product trials, visit https://www.melissa.com/ or call 1-800-MELISSA (635-4772).

Media contacts

Greg Brown

Vice President, Global Marketing, Melissa

greg.brown@Melissa.com

+1-800-635-4772 x1130 

Jacqueline Zerbst

MPowered PR for Melissa

pr@mpoweredpr.com

+1-877-794-6777

Source: Melissa

--BERNAMA

ADAGIO THERAPEUTICS ANNOUNCES EXPANSION OF PATIENT POPULATION IN GLOBAL PHASE 2/3 CLINICAL TRIAL OF ADG20 FOR THE PREVENTION OF COVID-19

Independent Data Monitoring Committee Supports Expansion to Adolescents and Pregnant and Nursing Women Based on Safety and Tolerability Data from Phase 2 Lead-In

WALTHAM, Mass., Sept 13 (Bernama-GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 has provided a recommendation to expand Phase 3 trial enrollment to include adolescents and pregnant or nursing women, as well as to decrease the protocol-specified, post injection monitoring time. The IDMC’s assessments are based on their review of unblinded safety and tolerability data from 200 participants enrolled in the Phase 2 lead-in portion of the trial. Adagio remains blinded to the data and plans to implement the IDMC recommendations for the Phase 3 portion of the trial. EVADE is being conducted globally, including in regions where there is a high prevalence of SARS-CoV-2 variants of concern, to evaluate the ability of a single, intramuscular dose of ADG20 to prevent COVID-19 in both pre- and post-exposure settings.

“Given the urgent need for additional treatment and preventative options for COVID-19, particularly in vulnerable populations, we are pleased that an independent assessment of the safety data from the lead-in portion of EVADE supported inclusion of adolescents and pregnant or nursing women in the next phase of the study,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “Based on the potent and broad activity of ADG20 in non-clinical studies, as well as its extended half-life and ease of administration, we believe this antibody has the potential to become a preferred prophylactic option for COVID-19, particularly for vulnerable groups such as children and the immunocompromised, for whom there are currently limited or no available options.”

The EVADE trial is a global, multi-center, double-blind, placebo-controlled clinical trial evaluating ADG20 in two independent cohorts. The first cohort (post-exposure prophylaxis) is designed to assess the safety and efficacy of ADG20 compared to placebo for the prevention of COVID-19 after exposure to an individual with laboratory confirmed SARS-CoV-2 infection. The second cohort (pre-exposure prophylaxis) is designed to assess the efficacy and safety of ADG20 compared to placebo in individuals who are at increased risk for SARS-CoV-2 infection due to occupational, housing or recreational situations, and in individuals who are at increased risk of poor vaccine response, including individuals with compromised immune systems or other co-morbidities. The primary efficacy endpoint in both cohorts is the prevention of laboratory confirmed, symptomatic COVID-19. For more information on the EVADE trial, please visit https://clinicaltrials.gov/ct2/show/NCT04859517.

The clinical development program for ADG20 includes two additional trials: the ongoing Phase 1 clinical trial of ADG20 in healthy volunteers and the ongoing STAMP trial evaluating ADG20 as a treatment for high-risk individuals with mild or moderate COVID-19 (see clinicaltrials.gov).

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is formulated at high concentrations, enabling intramuscular administration, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com 

Source: Adagio Therapeutics, Inc. 

--BERNAMA

SEAFOOD LEGACY CO., LTD. ANNOUNCES TOKYO SUSTAINABLE SEAFOOD SUMMIT 2021 REGISTRATION OPENS

 

Build Blue Economy Toward 2030: Changing Japanese Seafood Industry by DX and ESG Investment

TOKYO, Aug 27 (Bernama-BUSINESS WIRE) -- The Tokyo Sustainable Seafood Summit 2021 (TSSS2021) will be held from 11th to 13th October, Monday to Wednesday, 2021. The event is hosted by Seafood Legacy Co., Ltd. (hereinafter "Seafood Legacy '') and Nikkei ESG and co-sponsored by Walton Family Foundation, David and Lucile Packard Foundation.
 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005032/en/ 

The theme of this year's summit is "Build Blue Economy Toward 2030: Changing Japanese Seafood Industry by DX and ESG Investment." With its eyes set on the blue economy and the achievement of the SDGs by their 2030 deadline, the summit will focus on DX (Digital Transformation) and ESG investment aimed at accelerating the move towards sustainability in the Japanese seafood industry.

The Tokyo Sustainable Seafood Symposium, the predecessor to this year's Tokyo Sustainable Seafood Summit, has been held yearly since 2015 and has grown into one of Asia's largest and leading events in the sustainable seafood movement, with its participation growing each year. Last year, there were 108 speakers and 3,800 attendees (online viewership).

With the growing global interest in sustainability, and as symbolized by the idea of the "blue economy," there is a growing movement towards sustainability in the seafood industry and other ocean-based economies.

In particular, a revision to Japan's Fisheries Act came into effect in December 2020, with a law enacted to adjust and improve distribution (Domestic Trade of Specific Marine Animals and Plants Act). The policy has made major strides towards improving sustainability. Along with these changes, there are also signs that digital transformation will help promote sustainability in the seafood industry. Financial institutions have also launched initiatives that leverage ESG investment to improve industry sustainability.

The name for the event was changed from "symposium" to "summit" to better reflect the aim of realizing a more practical movement. The goal is to make the summit an event where, in addition to focusing on DX and ESG investment, we can join with speakers and participants to discuss how, in the ten years to the 2030 SDGs deadline, we can best build the blue economy.

In addition to sharing the latest information as was done in previous events, this year's event will use online functionality to provide a place where those earnestly seeking to promote sustainability in the seafood industry can interact with one another.

For three days, the summit will allow experts, both domestic and foreign, to join with other related persons to discuss the Japanese seafood industry, with the goal of passing on abundant oceans and a sustainable economy to the generations that follow. We would appreciate your sharing this information via your respective mediums.

Outline

·Title: Tokyo Sustainable Seafood Summit 2021 (TSSS2021)
·Theme: BUILD BLUE ECONOMY TOWARD 2030: Changing Japanese Seafood Industry by DX and ESG Investment
·Date / Time: 11th to 13th October, Monday to Wednesday, 2021
·Venue: Online
·Participation Fee: ¥5,000 per person for full three days (tax excluded)
·Simultaneous Japanese-English Interpretation 
 

For more details and registration, please visit: https://sustainableseafoodnow.com/2021/en/ 

During the event period, we will also hold the 3^rd Japan Sustainable Seafood Award, which recognizes efforts toward stimulating Japan’s sustainable seafood movement.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005032/en/ 

Contact

Contact regarding this announcement:
Miki Yamaoka miki.yamaoka@seafoodlegacy.com
Mariko Arikawa mariko.arikawa@seafoodlegacy.com
Tel: +81-80-3550-2920
Seafood Legacy Co., Ltd. 

Source : Seafood Legacy Co., Ltd. 

--BERNAMA

Hyatt enters definitive agreement to acquire Apple Leisure Group

KUALA LUMPUR, Aug 16 -- Hyatt Hotels Corporation has announced that Hyatt has entered into a definitive agreement to acquire Apple Leisure Group (ALG), a leading luxury resort-management services, travel and hospitality group, from affiliates of each of KKR and KSL Capital Partners LLC for US$2.7 billion in cash. (US$1 = RM4.241)

The transaction is anticipated to close in the fourth quarter of 2021, subject to customary closing conditions, according to a statement.

ALG’s resort brand management platform AMResorts® provides management services to the largest portfolio of luxury all-inclusive resorts in the Americas under the AMR™ Collection brand portfolio.

The acquisition also includes ALG’s membership offering, Unlimited Vacation Club®, travel distribution business ALG Vacations®, as well as destination management services and travel technology assets.

Following completion of the transaction, ALG’s business will continue to be led by current ALG Chief Executive Officer (CEO) Alejandro Reynal and the current ALG leadership team. Reynal will become a member of Hyatt’s executive leadership team and report to Hyatt CEO Mark Hoplamazian.

Hoplamazian, who is also Hyatt president, said: “The addition of ALG’s properties will immediately double Hyatt’s global resorts footprint.”

“ALG’s portfolio of luxury brands, leadership in the all-inclusive segment and large pipeline of new resorts will extend our reach in existing and new markets, including in Europe, and further accelerate our industry-leading net rooms growth.

“Importantly, the combination of this value-creating acquisition and the US$2 billion increase in our asset sale commitment will transform our earnings profile, and we expect Hyatt to reach 80 per cent fee-based earnings by the end of 2024.”

ALG’s hotel portfolio consists of over 33,000 rooms operating in 10 countries. The portfolio has grown from nine resorts in 2007, to approximately 100 properties by 2021-end and has a pipeline of 24 executed deals with a large number of additional hotels in the development process.

At closing, Hyatt expects to fund more than 80 per cent of the purchase with a combination of US$1.0 billion of cash on hand and new debt financings, and the remainder with approximately US$500 million from equity financing.

Hyatt has secured a US$1.7 billion financing commitment from J.P. Morgan. Cash proceeds from the US$2 billion asset sale programme are expected to be used to pay down debt, including debt incurred to fund the acquisition.

More details at www.hyatt.com.

-- BERNAMA

Kioxia exceeds performance boundaries with Ver. 3.1 UFS embedded flash memory devices

  

KUALA LUMPUR, Aug 11 -- Kioxia Corporation, a world leader in memory solutions, has announced sampling of its newest generation of 256 and 512 gigabyte (GB) Universal Flash Storage (UFS) Ver. 3.1 embedded flash memory devices.

Housed in 0.8 and 1.0mm-high packages, the new products improve performance by approximately 30 per cent for random read and approximately 40 per cent for random write – making them thinner and faster than their predecessors.

According to a statement, Kioxia’s new UFS devices utilise the company’s high-performance fifth-generation BiCS FLASH™ 3D flash memory and are targeted to a variety of mobile applications including leading-edge smartphones.

The broad set of power and space conscious applications that utilise embedded flash memory continues to need higher performance and density, and UFS has increasingly been the solution of choice. 

Kioxia is committed to uplifting the world with ‘memory’ by offering products, services and systems that create choice for customers and memory-based value for society.

Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centres.

-- BERNAMA

DON'T MISS AUSTRALIA'S LARGEST ABORIGINAL AND TORRES STRAIT ISLANDER VISUAL ART EVENT

 DARWIN, Australia, Aug 3 (Bernama-GLOBE NEWSWIRE) -- The Darwin Aboriginal Art Fair (DAAF) will open Friday 6 August via its cutting-edge digital platform, connecting audiences around the world with Australia’s Aboriginal and Torres Strait Islander creatives.

Presented by Darwin Aboriginal Art Fair Foundation (DAAFF), now in its 15^th year, the DAAF program will run from 6-11 August. The program features a highly anticipated digital art fair and an online Public Program that includes artist masterclasses and artists talks.

DAAFF will also showcase two First Nations fashion events including the annual National Indigenous Fashion Awards (NIFA) and the winner announcement will be live streamed across NITV’s social media channels on 3 August, direct from the Darwin Convention Centre, Australia. The vibrant Country to Couture runway will also be presented on 4 August. 

http://mrem.bernama.com/viewsm.php?idm=40681

Teledyne unveils compact thermal camera core

KUALA LUMPUR, Aug 4 -- Teledyne, a leading developer and manufacturer of high-performance digital cameras and custom imaging solutions via its Teledyne DALSA product lines, has introduced the MicroCalibir™, a new compact, low-power camera platform.

This latest uncooled thermal camera platform features the smallest VGA IR core module on the market, making it ideal for OEM drones, handhelds, helmet-mounted and vehicular integration products.

According to a statement, the development of the small and lightweight MicroCalibir is a result of the latest advances made by Teledyne DALSA’s integration of their in-house 12 μm microbolometer pixel technology with a deep-ADC ROIC circuit.

Its pocket-sized 21 x 21 mm format offers the latest Size Weight and Power (SWaP) optimisation for this type of LWIR imager, with very high dynamic range.

Furthermore, the cameras can reach very low, sub-30mK, NETD levels by utilising advanced, user selectable noise filtering algorithms.

The MicroCalibir platform delivers accurate and high-end thermal capabilities and can be configured by resolution, field of view, and frame rate, delivering optimal performance in applications including UAVs, security and surveillance, outdoor recreation/personal vision systems, and firefighting.

MicroCalibir cameras and cores are available in QVGA and VGA resolutions and a variety of lens options. Its modular design allows for different interface options, for today and for the future. 

Current available interfaces are LVCMOS, and USB2, a CSI2 version will follow later in 2021.

-- BERNAMA